FDA Approves Setmelanotide for Obesity in Bardet-Biedl Syndrome ...Middle East

The FDA cleared setmelanotide (Imcivree) for people age 6 and older with obesity due to a rare genetic disorder, Bardet-Biedl Syndrome, adding to its approval for other rare diseases causing obesity. FDA Approvals

Hence then, the article about fda approves setmelanotide for obesity in bardet biedl syndrome was published today ( Friday 17/06/2022 - 02:32 PM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Approves Setmelanotide for Obesity in Bardet-Biedl Syndrome )

Also on site :

• Oddity Tech Ltd. Group Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ODD
• ‘Technofascism’: Critics accuse Palantir of pushing AI war doctrine
• Jennifer Aniston Shares Surprising Reaction To Ex-Husband Justin Theroux's Baby Announcement